Cagrilintide is a long-acting amylin analog in Phase III clinical trials. Combined with semaglutide (CagriSema), it produced 20.4% average body weight loss over 68 weeks in REDEFINE 1. It's not yet FDA-approved. TelosRX provides asynchronous telehealth evaluation for currently available compounded GLP-1 therapies.
If you've been tracking obesity drug news, cagrilintide is probably on your radar. The Phase III REDEFINE results got real attention — and for good reason. But there's noise about what it is, when it might be available, and what to do in the meantime. This covers what the data actually shows.
What Is Cagrilintide?
Cagrilintide is a synthetic analog of amylin — a hormone your pancreas releases alongside insulin after meals. Amylin signals fullness to your brain, slows gastric emptying, and suppresses glucagon. Think of it as insulin's quieter partner: not talked about much, but doing real work.
In people with obesity, amylin signaling is often blunted. Natural amylin also breaks down quickly in the bloodstream, limiting clinical use. Cagrilintide addresses this with molecular modifications that extend its half-life, enabling once-weekly subcutaneous dosing.
It acts on amylin receptors 1 and 3 (AMY1R and AMY3R) in brainstem regions that process satiety signals. This is a fundamentally different target than GLP-1 receptor agonists like semaglutide or tirzepatide.
How Cagrilintide Works: The Amylin Pathway
GLP-1 receptor agonists suppress appetite via the incretin pathway. Cagrilintide uses the amylin pathway — different receptors, different brain regions, complementary result.
The practical effect: reduced food intake, slower gastric emptying, and stronger satiety signals after meals. Preclinical research published in eBioMedicine confirmed that cagrilintide's weight-lowering effect depends on AMY1R and AMY3R brain activation. Knockout mice lacking these receptors showed significantly blunted response.
This explains why combining cagrilintide with semaglutide produces results greater than either drug alone. You're hitting two separate appetite-signaling systems simultaneously.
Cagrilintide vs. Semaglutide: Key Differences
Semaglutide targets the GLP-1 receptor. Cagrilintide targets amylin receptors. Here's how they compare alongside tirzepatide:
| Feature | Cagrilintide | Semaglutide | Tirzepatide |
|---|---|---|---|
| Primary receptor | AMY1R / AMY3R (amylin) | GLP-1R | GLP-1R / GIPR |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
| FDA approval status | Not approved (Phase III) | Approved (Wegovy) | Approved (Zepbound) |
| Weight loss — monotherapy | ~11.5% at 68 weeks | ~14.9% at 68 weeks | ~20% at 72 weeks |
| Weight loss — CagriSema combo | 20.4% (with semaglutide) | 14.9% (alone) | Not studied in this combination |
| Legally compoundable? | No — no approved reference product | Subject to FDA shortage status | Subject to FDA shortage status |
Cagrilintide monotherapy (11.5%) trails semaglutide and tirzepatide as standalone agents. The combination changes that picture substantially — but access to CagriSema awaits FDA review.
CagriSema: What the REDEFINE 1 Trial Found
REDEFINE 1 was a Phase III randomized controlled trial of 3,417 adults with obesity (BMI ≥30 or ≥27 with a complication). Participants received once-weekly CagriSema 2.4 mg each, semaglutide alone, cagrilintide alone, or placebo for 68 weeks.
Key results, published in the New England Journal of Medicine:
- CagriSema group: −20.4% mean body weight loss
- Semaglutide alone: −14.9%
- Cagrilintide alone: −11.5%
- Placebo: −4.0%
- 91.4% of CagriSema participants achieved ≥5% weight loss vs. 31.5% on placebo
- Waist circumference: −13.4 cm with CagriSema
- Systolic blood pressure: −6.7 mmHg with CagriSema
The REDEFINE 2 trial evaluated CagriSema in adults with type 2 diabetes and obesity, also published in NEJM. Both trials show consistent superiority of the combination over either agent alone.
Adverse events were predominantly gastrointestinal — nausea, constipation, vomiting — consistent with GLP-1 class effects. Discontinuation due to adverse events was rare, but highest in the CagriSema group.
Cagrilintide Side Effects
The safety profile observed in REDEFINE trials is primarily gastrointestinal:
- Nausea, especially early in titration
- Constipation
- Vomiting, typically with rapid dose escalation
- Early satiety and mild bloating
These effects were dose-dependent and generally transient. 92.3% of CagriSema participants reported at least one adverse event; most were mild to moderate. Two deaths occurred during the trial but were determined to be unrelated to treatment.
Long-term cardiovascular outcomes data are still being collected. Cagrilintide's structural similarity to calcitonin raises the same theoretical C-cell concern that exists for GLP-1 receptor agonists.
Who Should Not Use Cagrilintide
Based on trial exclusion criteria and the drug's receptor profile, cagrilintide requires caution or is contraindicated in:
- Personal or family history of medullary thyroid carcinoma (MTC) — calcitonin receptor overlap
- Multiple endocrine neoplasia type 2 (MEN2) — same receptor concern
- Severe gastroparesis or GI dysmotility — drug further slows gastric emptying
- Pregnancy or breastfeeding — no safety data available
- Severe renal impairment (eGFR <30) — insufficient pharmacokinetic data
This contraindication profile is why any future access to cagrilintide would require thorough provider evaluation — not a self-screening questionnaire.
Is Cagrilintide FDA Approved?
No. As of 2026, cagrilintide is not FDA-approved for any indication. It remains in Phase III clinical investigation under the REDEFINE program.
It cannot be legally prescribed off-label. It also cannot be used in compounding pharmacies under current FDA rules. Unlike compounded semaglutide or tirzepatide, there is no approved reference product to support a legal compounding pathway for cagrilintide.
Any provider currently offering "compounded cagrilintide" is operating outside federal law. This isn't nuance — it's a clear regulatory boundary.
What's Next for Cagrilintide Research
The REDEFINE program covers obesity without diabetes (REDEFINE 1), obesity with type 2 diabetes (REDEFINE 2), and cardiovascular outcomes. Regulatory submission is expected after full trial completion, but no confirmed FDA approval timeline exists as of this writing.
Researchers are also exploring whether cagrilintide's dual mechanism benefits patients who plateau on GLP-1 monotherapy — a common clinical scenario. Combination approaches with other agents are also under study.
If cagrilintide reaches FDA approval, it would likely launch as a branded injectable, similar to how semaglutide launched as Ozempic then Wegovy — not immediately entering a compounding pathway.
What to Do in the Meantime
Cagrilintide isn't here yet. The patients most likely to respond when it does arrive are those who've already built a metabolic foundation with current therapies.
Compounded tirzepatide and semaglutide are available through TelosRX's asynchronous telehealth process — subject to medical approval by a licensed provider. You submit your intake, a provider reviews it, and if appropriate, a prescription is issued. No live appointment required.
If you've tried one GLP-1 and want to understand where newer options like retatrutide fit in, or want to compare your current therapy against alternatives, the GLP-1 comparison guide at TelosRX is a good starting point.
Frequently Asked Questions
Is cagrilintide FDA approved?
No. As of 2026, cagrilintide is not FDA-approved for any indication. It's in Phase III clinical trials under the REDEFINE program. It cannot be legally prescribed or compounded in the United States outside of clinical trials.
What is CagriSema and how much weight loss does it produce?
CagriSema is the combination of cagrilintide 2.4 mg and semaglutide 2.4 mg, both given as once-weekly injections. In the REDEFINE 1 Phase III trial, CagriSema produced an average 20.4% body weight loss over 68 weeks — the largest result seen in a major obesity drug trial to date.
How does cagrilintide differ from semaglutide or tirzepatide?
Semaglutide targets the GLP-1 receptor. Tirzepatide targets GLP-1 and GIP receptors. Cagrilintide targets amylin receptors (AMY1R and AMY3R) in the brain. These are separate systems, which is why combining cagrilintide with semaglutide produces greater weight loss than either drug alone.
What are the side effects of cagrilintide?
In clinical trials, the most common side effects were gastrointestinal: nausea, constipation, vomiting, and early satiety. These were dose-dependent and generally transient. Contraindications include a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
When will cagrilintide be available?
No confirmed FDA approval timeline exists as of 2026. The REDEFINE trials are ongoing, and regulatory submission follows trial completion. Even after approval, it would likely launch as a branded injectable — not a compounded product.
Can I get cagrilintide through a telehealth provider?
Not legally, not yet. Any telehealth or compounding provider claiming to offer cagrilintide today is operating outside FDA regulations. Currently available compounded GLP-1 options — tirzepatide and semaglutide — can be evaluated through asynchronous telehealth services, subject to medical approval by a licensed provider.
Is cagrilintide better for weight loss than tirzepatide?
As monotherapy, cagrilintide (11.5%) underperforms tirzepatide (approximately 20%) in available trial data. Combined with semaglutide, CagriSema reaches 20.4%. Direct comparisons between CagriSema and tirzepatide are not yet available from published Phase III data.
Who should not use cagrilintide?
People with a personal or family history of medullary thyroid carcinoma (MTC), MEN2, severe gastroparesis, or severe renal impairment (eGFR less than 30) should not use cagrilintide. Pregnancy and breastfeeding are also exclusions due to lack of safety data.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.